Literature DB >> 8587389

ETB receptors promote proliferation and migration of endothelial cells.

M Ziche1, L Morbidelli, S Donnini, F Ledda.   

Abstract

We investigated endothelin-1 and -3 (ET-1, ET-3) effects on proliferation and migration of endothelial cells isolated from bovine adrenal capillaries (BACEs) and from human umbilical veins (HUVECs). Dose-dependent proliferation was produced by ET-1 and ET-3 in both cell lines, with maximal effects at 0.1 nM concentration. ET-1 and ET-3 also stimulated BACE and HUVEC mobilization in a dose-dependent manner. The selective agonist for the ETB receptor ET(16-21) showed the same effects as ET-1 and ET-3 on proliferation and migration in both cell lines. The ETB receptor antagonist IRL 1038 (1 microM) blocked the migration induced by both ET-3 and ET[16-21], whereas the ETA receptor antagonist BQ 123 (1 microM) was ineffective. We conclude that endothelins, by favoring endothelial cell growth and mobilization, can contribute to neovascularization through an autocrine mechanism that requires ETB receptor activation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8587389

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  11 in total

Review 1.  Angiogenesis in cancer: the role of endothelin-1.

Authors:  K Dawas; M Loizidou; A Shankar; H Ali; I Taylor
Journal:  Ann R Coll Surg Engl       Date:  1999-09       Impact factor: 1.891

2.  Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB receptor, NADPH oxidase and caveolin-1.

Authors:  Feng Dong; Xiaochun Zhang; Loren E Wold; Qun Ren; Zhaojie Zhang; Jun Ren
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

Review 3.  Endothelin B receptor, a new target in cancer immune therapy.

Authors:  Lana E Kandalaft; Andrea Facciabene; Ron J Buckanovich; George Coukos
Journal:  Clin Cancer Res       Date:  2009-06-30       Impact factor: 12.531

4.  Ontogeny of endothelins-1 and -3, their receptors, and endothelin converting enzyme-1 in the early human embryo.

Authors:  M Brand; J M Le Moullec; P Corvol; J M Gasc
Journal:  J Clin Invest       Date:  1998-02-01       Impact factor: 14.808

5.  Modulation of human colon tumor-stromal interactions by the endothelin system.

Authors:  G Egidy; L Juillerat-Jeanneret; J F Jeannin; P Korth; F T Bosman; F Pinet
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

6.  Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer.

Authors:  Sun-Jin Kim; Jang Seong Kim; Seung Wook Kim; Emily Brantley; Seok Joong Yun; Junqin He; Marva Maya; Fahao Zhang; Qiuyu Wu; François Lehembre; Urs Regenass; Isaiah J Fidler
Journal:  Neoplasia       Date:  2011-02       Impact factor: 5.715

7.  Different endothelins stimulate cytokine production by peritoneal macrophages and microglial cell line.

Authors:  L Speciale; K Roda; M Saresella; D Taramelli; P Ferrante
Journal:  Immunology       Date:  1998-01       Impact factor: 7.397

8.  The endothelin system in Morris hepatoma-7777: an endothelin receptor antagonist inhibits growth in vitro and in vivo.

Authors:  Thiemo Pfab; Gisela Stoltenburg-Didinger; Christoph Trautner; Michael Godes; Christian Bauer; Berthold Hocher
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

Review 9.  Endothelin-1 as a target for therapeutic intervention in prostate cancer.

Authors:  E Scott Kopetz; Joel B Nelson; Michael A Carducci
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

10.  Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cells.

Authors:  Lan Coffman; Collin Mooney; Jaeyoung Lim; Shoumei Bai; Ines Silva; Yusong Gong; Kun Yang; Ronald J Buckanovich
Journal:  Cancer Biol Ther       Date:  2012-11-28       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.